Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539123 · ClinicalTrials.gov registry record · NA
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 234
- Enrollment target
NCT00539123 is a NA study that has completed, run by Yale University. The registered enrollment target is 234 participants.
The verdict
NCT00539123, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 234 participants
- Enrollment target
Study Summary
A randomized clinical trial evaluating whether Behavioral Drug and HIV Risk Reduction Counseling (BDRC), abstinence-contingent take-home buprenorphine (ACB), or the combination of the two improve efficacy and cost-effectiveness of standard buprenorphine treatment for opiate-dependent individuals in Malaysia.
Interventions
- BEHAVIORAL behavioral drug and HIV risk reduction counseling (BDRC)
- BEHAVIORAL abstinence-contingent buprenorphine (ACB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539123
The ClinicalTrials.gov registry entry for NCT00539123 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which behavioral drug and HIV risk reduction counseling (BDRC) is the first listed.
NCT00539123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539123 about?
NCT00539123 is a clinical study titled "Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia". A randomized clinical trial evaluating whether Behavioral Drug and HIV Risk Reduction Counseling (BDRC), abstinence-contingent take-home buprenorphine (ACB), or the combination of the two improve efficacy and cost-effectiveness of standard buprenorphine treatment for opiate-dependent individuals in ...
What is the current status of trial NCT00539123?
This trial is currently completed. It is a NA study. The enrollment target is 234 participants. The study started on 2007-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00539123?
The interventions under investigation include: behavioral drug and HIV risk reduction counseling (BDRC) (BEHAVIORAL), abstinence-contingent buprenorphine (ACB) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00539123?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.